With annual expiries peaking at $104bn in 2028, biopharma faces a concentrated risk that could reshape the industry’s growth outlook.
Share:
This webinar will unpack the scale of the impending patent cliff, spotlight the top 10 drugs facing expiry, and reveal how large pharma’s growth gap is driving new portfolio strategies.
The patent cliff refers to the period when major prescription drugs lose exclusivity, exposing them to generic and biosimilar competition. This can result in significant revenue loss and strategic challenges for pharma companies.
Brands like Keytruda, Darzalex, Eliquis, and Opdivo are among the top ten expiries, with Merck, Bristol Myers Squibb, and Pfizer facing the largest portfolio risks.
